Dupilumab
Dupilumab is a fully human monoclonal antibody used as a targeted therapy for type 2 inflammatory diseases.
Dupilumab is a fully human monoclonal antibody used as a targeted therapy for type 2 inflammatory diseases. Its principal mechanism is blockade of interleukin-4 receptor alpha, which inhibits signaling by interleukin-4 and interleukin-13, two central cytokines in type 2 immune responses. By dampening this pathway, dupilumab reduces inflammatory activity that contributes to diseases such as atopic dermatitis, asthma, and eosinophilic esophagitis.
Clinically, dupilumab is notable for its broad use across multiple immune-mediated conditions driven by type 2 inflammation. Recent research continues to evaluate its effectiveness, safety, and comparative performance against other therapies, while also examining adverse effects such as ocular surface disease and eosinophilia. It is also being studied in special populations, including young children and patients with complex comorbid inflammatory disease.
Where the papers sit
25 papers from the last 6 months study dupilumab directly · updated from PubMed 14 Nov 2026
Study type 2 clinical trials · 13 observational · 5 human data · 1 preclinical · 4 unclassified
Themes 4 themes · 2 new directions
-
Atopic Dermatitis Treatment
Atopic dermatitis care is moving toward comparative, real-world treatment selection rather than efficacy alone. Dupilumab is being assessed against upadacitinib through response trajectories, poor-responder risk factors, benefit-risk balance, and herpetic infection signals. Special-population safety, oral microbiome changes, ocular outcomes, and coccidioidomycosis broaden surveillance. Cutaneous T-cell lymphoma emerging during treatment underscores diagnostic caution when dermatitis fails to respond.
10 papers · 40%
-
Type 2 Inflammatory Disease
Type 2 inflammatory disease management is moving toward steroid-sparing, real-world use of dupilumab. Severe-asthma cohorts assess reductions in inhaled corticosteroids and other maintenance therapy, while chronic rhinosinusitis with nasal polyps follow-up emphasizes two-year effectiveness and safety. COPD data test whether this approach extends beyond classic indications, and a case report addresses complicated nasal polyposis. Evidence in chronic spontaneous urticaria remains exploratory within this broader inflammatory spectrum.
6 papers · 24%
-
Eosinophilic and Atopic Disease
Eosinophilic and atopic disease treatment is broadening beyond dermatitis and asthma to eosinophilic esophagitis and gastritis. Dupilumab is being evaluated in pediatric liver-transplant recipients and multicentre real-world paediatric cohorts, alongside placebo-controlled results in eosinophilic gastritis. IL-4, IL-13, and eosinophil biology recur as the mechanistic frame, while seasonal cytokine variation may affect interpretation. Pediatric pharmacovigilance and registry data are building the safety and selection evidence needed for wider use.
6 papers · 24%
-
Others — Immune-Mediated Skin and Lung Disease
Bullous pemphigoid reports focus on dupilumab as an adjunct or steroid-sparing option, including immune checkpoint inhibitor-associated disease and Norwegian scabies treated with ivermectin. Complete remission and corticosteroid reduction are recurring aims, but evidence remains case-based. A separate pulmonary fibrosis study points to IL-4R/JAK/STAT disruption and macrophage-fibroblast crosstalk as a possible antifibrotic mechanism. The cluster has no single disease trajectory beyond exploratory dupilumab use in immune-mediated conditions.
3 papers · 12%
Dupilumab is presented as an antifibrotic intervention in idiopathic pulmonary fibrosis
The idiopathic pulmonary fibrosis mouse model and macrophage–fibroblast coculture system treated dupilumab not as therapy for an established type 2 inflammatory disease, but as a direct antifibrotic agent. Dupilumab suppressed TGF-β1-induced fibroblast activation, inhibited the profibrotic macrophage phenotype and macrophage-induced myofibroblast activation, and improved pulmonary fibrosis-related outcomes in bleomycin-challenged mice. This extends dupilumab into experimental treatment of fibrotic lung disease through macrophage–fibroblast and IL4R/JAK/STAT mechanisms rather than its clinical role in type 2 inflammatory disorders 42747578Sep.
Dupilumab is presented as a possible unmasker of cutaneous T-cell lymphoma requiring diagnostic reassessment
The cutaneous T-cell lymphoma emerging during long-term dupilumab therapy in a patient with longstanding atopic diathesis challenged the assumption that a stable or presumed atopic dermatitis course could continue to be managed as dermatitis; the patient instead developed patch-stage mycosis fungoides after more than five years, with the authors raising the possibility that dupilumab had unmasked previously unrecognised lymphoma. Dupilumab therefore acquires a new role as a potential contributor to a diagnostic phenomenon and as a reason to reassess atypical or treatment-resistant eruptions, rather than simply as therapy for inflammatory disease 42805618Sep.
Papers
The 25 papers from the last 6 months that study dupilumab directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Atopic Dermatitis Treatment (10)
- Dupilumab in Atopic Dermatitis - Rate of Poor Responders and Potential Risk Factors from the TREATgermany Registry. Acta dermato-venereologica · 5 Nov 2026 PMID 42986187
- Dual Remission of Atopic Dermatitis and Frequently Relapsing Nephrotic Syndrome With Dupilumab. Pediatrics · 27 Oct 2026 PMID 42946004
- Characterization of oral microbiome in atopic dermatitis patients treated with dupilumab or upadacitinib. Clinical oral investigations · 6 Oct 2026 PMID 42836883
- Corrigendum: Safety and Effectiveness Profile of Dupilumab in the Treatment of Atopic Dermatitis in Special Populations. Acta dermato-venereologica · 2 Oct 2026 PMID 42825424
- Cutaneous T-cell lymphoma emerging during long-term dupilumab therapy in a patient with longstanding atopic diathesis: diagnostic challenges and mechanistic considerations. BMJ case reports · 28 Sept 2026 PMID 42805618
- Ocular Safety of Dupilumab Compared With IL-5 Inhibitors in Asthma. The journal of allergy and clinical immunology. In practice · 23 Sept 2026 PMID 42777916
- Coccidioidomycosis in Patients Treated with Dupilumab: A Descriptive Case Series. Mycopathologia · 7 Sept 2026 PMID 42704511
- Comparative pharmacovigilance of herpetic infections with dupilumab and Janus kinase inhibitors in atopic dermatitis. Clinical and experimental dermatology · 8 Jun 2026 PMID 42252930
- Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial. The Journal of dermatological treatment · 1 Jun 2026 PMID 42223292
- Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis). Dermatology and therapy · 29 May 2026 PMID 42213297
Type 2 Inflammatory Disease (6)
- A case of complicated chronic rhinosinusitis with nasal polyps treated with dupilumab, in the UK: a case report. Journal of medical case reports · 13 Nov 2026 PMID 43026555
- Real-world effectiveness of dupilumab in patients with severe asthma in Europe: Findings from the EU-ADVANTAGE study. Respiratory medicine · 10 Oct 2026 PMID 42858834
- Real-world effectiveness of dupilumab in COPD: a German multicenter analysis. Respiratory research · 7 Oct 2026 PMID 42839285
- De-escalation of inhaled corticosteroids and other maintenance asthma therapies in dupilumab-treated patients with severe asthma: a real-world study. Respiratory medicine · 3 Aug 2026 PMID 42546934
- Dupilumab effectiveness and safety in patients with CRSwNP: two year results from AROMA registry. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 27 Jul 2026 PMID 42508565
- Dupilumab in Difficult-to-treat Chronic Spontaneous Urticaria: A Real-world Multicentre Cohort Study. Acta dermato-venereologica · 6 Jul 2026 PMID 42403314
Eosinophilic and Atopic Disease (6)
- Dupilumab for paediatric eosinophilic esophagitis: a multicentre real-world study. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 17 Sept 2026 PMID 42754470
- Pharmacovigilance signals of dupilumab among pediatric patients: A real‑world analysis based on the FAERS database. Human vaccines & immunotherapeutics · 4 Sept 2026 PMID 42695738
- Seasonal variation in cytokine profiles in atopic dermatitis patients treated with dupilumab. Journal of immunotoxicology · 26 Jun 2026 PMID 42360862
- Dupilumab Is Safe and Efficacious for Treatment of Eosinophilic Esophagitis and Atopic Dermatitis in Pediatric Liver Transplant Recipients: A Case Series. Pediatric transplantation · 26 Jun 2026 PMID 42351377
- Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial. The lancet. Gastroenterology & hepatology · 24 Jun 2026 PMID 42341804
- Baseline Characteristics of Patients with Asthma Initiating Dupilumab in a Real-World Setting: The REVEAL Registry. Advances in therapy · 10 Jun 2026 PMID 42268495
Others — Immune-Mediated Skin and Lung Disease (3)
- Management of Bullous Pemphigoid and Norwegian Scabies with Dupilumab Plus Ivermectin. The American journal of tropical medicine and hygiene · 22 Sept 2026 PMID 42772271
- Dupilumab Alleviates Pulmonary Fibrosis by Interrupting Profibrotic Macrophage-Fibroblast Crosstalk and IL4R/JAK/STAT Signaling. Lung · 16 Sept 2026 PMID 42747578
- Efficacy and Safety of Dupilumab in Immune Checkpoint Inhibitor Induced Bullous Pemphigoid: A Spanish Multicentric Case Series. Acta dermato-venereologica · 21 May 2026 PMID 42163825
By study type
Clinical trials (2)
- Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial. The lancet. Gastroenterology & hepatology · 24 Jun 2026 PMID 42341804
- Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial. The Journal of dermatological treatment · 1 Jun 2026 PMID 42223292
Observational studies and case reports (13)
- A case of complicated chronic rhinosinusitis with nasal polyps treated with dupilumab, in the UK: a case report. Journal of medical case reports · 13 Nov 2026 PMID 43026555
- Dupilumab in Atopic Dermatitis - Rate of Poor Responders and Potential Risk Factors from the TREATgermany Registry. Acta dermato-venereologica · 5 Nov 2026 PMID 42986187
- Dual Remission of Atopic Dermatitis and Frequently Relapsing Nephrotic Syndrome With Dupilumab. Pediatrics · 27 Oct 2026 PMID 42946004
- Real-world effectiveness of dupilumab in patients with severe asthma in Europe: Findings from the EU-ADVANTAGE study. Respiratory medicine · 10 Oct 2026 PMID 42858834
- Cutaneous T-cell lymphoma emerging during long-term dupilumab therapy in a patient with longstanding atopic diathesis: diagnostic challenges and mechanistic considerations. BMJ case reports · 28 Sept 2026 PMID 42805618
- Management of Bullous Pemphigoid and Norwegian Scabies with Dupilumab Plus Ivermectin. The American journal of tropical medicine and hygiene · 22 Sept 2026 PMID 42772271
- Dupilumab for paediatric eosinophilic esophagitis: a multicentre real-world study. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 17 Sept 2026 PMID 42754470
- Coccidioidomycosis in Patients Treated with Dupilumab: A Descriptive Case Series. Mycopathologia · 7 Sept 2026 PMID 42704511
- Pharmacovigilance signals of dupilumab among pediatric patients: A real‑world analysis based on the FAERS database. Human vaccines & immunotherapeutics · 4 Sept 2026 PMID 42695738
- De-escalation of inhaled corticosteroids and other maintenance asthma therapies in dupilumab-treated patients with severe asthma: a real-world study. Respiratory medicine · 3 Aug 2026 PMID 42546934
- Dupilumab in Difficult-to-treat Chronic Spontaneous Urticaria: A Real-world Multicentre Cohort Study. Acta dermato-venereologica · 6 Jul 2026 PMID 42403314
- Dupilumab Is Safe and Efficacious for Treatment of Eosinophilic Esophagitis and Atopic Dermatitis in Pediatric Liver Transplant Recipients: A Case Series. Pediatric transplantation · 26 Jun 2026 PMID 42351377
- Efficacy and Safety of Dupilumab in Immune Checkpoint Inhibitor Induced Bullous Pemphigoid: A Spanish Multicentric Case Series. Acta dermato-venereologica · 21 May 2026 PMID 42163825
Human data, design not indexed (5)
- Real-world effectiveness of dupilumab in COPD: a German multicenter analysis. Respiratory research · 7 Oct 2026 PMID 42839285
- Characterization of oral microbiome in atopic dermatitis patients treated with dupilumab or upadacitinib. Clinical oral investigations · 6 Oct 2026 PMID 42836883
- Corrigendum: Safety and Effectiveness Profile of Dupilumab in the Treatment of Atopic Dermatitis in Special Populations. Acta dermato-venereologica · 2 Oct 2026 PMID 42825424
- Seasonal variation in cytokine profiles in atopic dermatitis patients treated with dupilumab. Journal of immunotoxicology · 26 Jun 2026 PMID 42360862
- Comparative pharmacovigilance of herpetic infections with dupilumab and Janus kinase inhibitors in atopic dermatitis. Clinical and experimental dermatology · 8 Jun 2026 PMID 42252930
Preclinical: animal, cell and lab studies (1)
- Dupilumab Alleviates Pulmonary Fibrosis by Interrupting Profibrotic Macrophage-Fibroblast Crosstalk and IL4R/JAK/STAT Signaling. Lung · 16 Sept 2026 PMID 42747578
Unclassified: not yet indexed with MeSH (4)
- Ocular Safety of Dupilumab Compared With IL-5 Inhibitors in Asthma. The journal of allergy and clinical immunology. In practice · 23 Sept 2026 PMID 42777916
- Dupilumab effectiveness and safety in patients with CRSwNP: two year results from AROMA registry. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 27 Jul 2026 PMID 42508565
- Baseline Characteristics of Patients with Asthma Initiating Dupilumab in a Real-World Setting: The REVEAL Registry. Advances in therapy · 10 Jun 2026 PMID 42268495
- Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis). Dermatology and therapy · 29 May 2026 PMID 42213297
Written from 25 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-25 by GPT. Drafted by language models from published abstracts; not medical advice.